SLC27A1 and breast cancer: Relapse free survival (RFS) time analysis was assessed in grade 1 (N = 108), grade 2 (N = 227) and grade 3 (N = 227) BC patients with high and low expression of FATP1/SLC27A1 (Fig. 1D) and also at the two different subgroups of grade 3 tumors: TNBC and luminal A. Patients with grade 3 disease and with high expression of FATP1/SLC27A1 showed a lower RFS comparing with grade 1 and 2 patients.